According to a recent LinkedIn post from Actithera, the company has added Erlend Eikeland Myrnes as Director of CMC Development in Oslo to lead strategic manufacturing and supply chain for its next‑generation radioligand therapies. The post highlights his technical background in radiopharmaceutical development and his role within the company’s Oslo R&D hub.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post suggests Actithera is formalizing its chemistry, manufacturing and controls capabilities to support progression of its tumor‑focused programs toward clinical supply. For investors, this move may indicate preparation for later‑stage development, greater manufacturing readiness and potential scalability in the radiopharmaceutical segment, which could strengthen the firm’s competitive position in oncology therapeutics.